STOCK TITAN

Anika Therapeutics, Inc. (NASDAQ: ANIK) CEO gets 12,840 shares via RSUs

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Anika Therapeutics, Inc. President and CEO Stephen D. Griffin reported the vesting of 12,840 restricted stock units on June 3, 2026, which converted into 12,840 shares of common stock at no cash cost as the second of three equal annual installments from a 38,520-RSU grant awarded on June 3, 2024.

To satisfy tax withholding obligations on this vesting, the issuer retained 3,769 shares at $14.41 per share. After these transactions, Griffin directly holds 45,973 shares of Anika common stock, including 739 shares acquired on May 14, 2026 under the company’s Employee Stock Purchase Plan.

Positive

  • None.

Negative

  • None.
Insider Griffin Stephen D.
Role President and CEO
Type Security Shares Price Value
Exercise Restricted Stock Unit 12,840 $0.00 $0.00
Exercise Common Stock 12,840 $0.00 $0.00
Exercise Price or Tax Liability Common Stock 3,769 $14.41 $54K
Holdings After Transaction: Restricted Stock Unit — 12,840 shares (Direct); Common Stock — 45,973 shares (Direct)
Footnotes (4)
  1. F1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
  2. F2. Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.
  3. F3. Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026.
  4. F4. On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award.
RSUs vested and converted 12,840 shares Restricted stock units vested and converted to common stock on June 3, 2026
Tax withholding shares 3,769 shares Shares retained by issuer to satisfy tax withholding on June 3, 2026 RSU vesting
Tax withholding price $14.41 per share Per-share value used when 3,769 shares were retained for tax obligations
RSU grant size 38,520 RSUs Grant awarded on June 3, 2024, vesting in three equal annual installments
Post-transaction holdings 45,973 shares Direct common stock holdings of Stephen D. Griffin after the June 3, 2026 transactions
ESPP shares 739 shares Shares acquired on May 14, 2026 under the Employee Stock Purchase Plan
Restricted Stock Unit financial
"Each restricted stock unit represents the contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
tax withholding obligations financial
"shares of common stock retained by the Issuer to satisfy tax withholding obligations"
Employee Stock Purchase Plan financial
"Includes 739 shares acquired on May 14, 2026 under the Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What RSU transaction did Anika Therapeutics (ANIK) CEO Stephen D. Griffin report?

Stephen D. Griffin reported the vesting and conversion of 12,840 RSUs into 12,840 shares of Anika common stock on June 3, 2026. This represented the second annual installment of a 38,520-RSU grant awarded on June 3, 2024.

How many shares were withheld for taxes in ANIK’s CEO Form 4 filing?

The issuer retained 3,769 shares of common stock at $14.41 per share to cover tax withholding obligations tied to the June 3, 2026 RSU vesting. These retained shares represent a tax-withholding disposition, not an open-market sale.

What is Stephen D. Griffin’s Anika Therapeutics (ANIK) shareholding after this filing?

Following the June 3, 2026 RSU vesting and tax withholding, Stephen D. Griffin directly holds 45,973 shares of Anika common stock. This total includes 739 shares acquired on May 14, 2026 through the company’s Employee Stock Purchase Plan.

What RSU grant schedule led to the June 3, 2026 vesting for ANIK’s CEO?

On June 3, 2024, Griffin received a grant of 38,520 RSUs, vesting in three equal annual installments starting June 3, 2025. The June 3, 2026 event reflects the second installment of 12,840 RSUs under that grant.

Were the ANIK CEO’s June 3, 2026 transactions open-market purchases or sales?

No. The filing shows RSU conversion (code M) into 12,840 shares and a tax-withholding disposition (code F) of 3,769 shares. There are no open-market purchase (P) or sale (S) transaction codes reported in this Form 4.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Griffin Stephen D.

(Last)(First)(Middle)
C/O ANIKA THERAPEUTICS, INC.
32 WIGGINS AVENUE

(Street)
BEDFORD MASSACHUSETTS 01730

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/03/2026M12,840A(1)49,742(2)D
Common Stock06/03/2026F3,769(3)D$14.4145,973D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)06/03/2026M12,840 (4) (4)Common Stock12,840$012,840D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
2. Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.
3. Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026.
4. On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award.
/s/ Stephen D. Griffin06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)